Full Press Release Details
NEW YORK and WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the Company’s participation in the Jefferies Global Healthcare Conference. Marino Garcia, Chief Executive Officer, will participate in a fireside chat on Thursday, June 5, 2025 at 9:55 a.m. EDT in New York City and will host one-on-one meetings with investors.
A live webcast of the Company’s presentation may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.
About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
Dianthus Therapeutics